No Data
Promising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.
Medicus Pharma Brief: Says Has Entered Into Standby Equity Purchase Agreement and Announced Intention to Voluntarily Delist From the TSX Venture Exchange (TSXV)
Medicus Pharma Ltd. Announces Change of Auditor
Medicus Pharma Ltd: Innovative D-MNA Product Positions Company for Success With Favorable Buy Rating
Medicus Pharma up 9% in Pre-market Trading as FDA Approves Anti-cancer Patch for Horses
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation From the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
